Pfizer's COVID-19 oral pill to be effective against omicron variant, CEO tells CNBC

• Pfizer CEO Bourla said he has a “very high level of confidence” that the company’s COVID-19 oral pill is effective against the omicron variant

• Bourla said Pfizer has already started work on a new vaccine, and it could be ready in less than 100 days

Pfizer Inc CEO Albert Bourla on Monday said he expects the drugmaker’s COVID-19 oral antiviral pill, Paxlovid, to be effective against the omicron variant of the virus.

“The good news when it comes to our treatment, it was designed with that in mind, it was designed with the fact that most mutations are coming in the spikes,” Bourla told CNBC. “So that gives me very high level of confidence that the treatment will not be affected, our oral treatment will not be affected by this virus.”